BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 16536473)

  • 41. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
    Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
    Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy.
    Danks MK; Morton CL; Krull EJ; Cheshire PJ; Richmond LB; Naeve CW; Pawlik CA; Houghton PJ; Potter PM
    Clin Cancer Res; 1999 Apr; 5(4):917-24. PubMed ID: 10213229
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antitumor effects of an antibody-carboxypeptidase G2 conjugate in combination with a benzoic acid mustard prodrug.
    Blakey DC; Valcaccia BE; East S; Wright AF; Boyle FT; Springer CJ; Burke PJ; Melton RG; Bagshawe KD
    Cell Biophys; 1993; 22(1-3):1-8. PubMed ID: 7889535
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Construction, expression and functional characterization of the β-lactamase with αv integrin ligands.
    Wang H; Shi PJ; Wu MF; Li N; Zhou XL; Fan FY
    Protein Pept Lett; 2010 Dec; 17(12):1562-5. PubMed ID: 20858201
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Construction and characterization of a fusion protein of single-chain anti-CD20 antibody and human beta-glucuronidase for antibody-directed enzyme prodrug therapy.
    Haisma HJ; Sernee MF; Hooijberg E; Brakenhoff RH; vd Meulen-Muileman IH; Pinedo HM; Boven E
    Blood; 1998 Jul; 92(1):184-90. PubMed ID: 9639515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft models.
    Meyer DL; Jungheim LN; Law KL; Mikolajczyk SD; Shepherd TA; Mackensen DG; Briggs SL; Starling JJ
    Cancer Res; 1993 Sep; 53(17):3956-63. PubMed ID: 8358723
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
    Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
    Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
    Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
    Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A phase I study of single administration of antibody-directed enzyme prodrug therapy with the recombinant anti-carcinoembryonic antigen antibody-enzyme fusion protein MFECP1 and a bis-iodo phenol mustard prodrug.
    Mayer A; Francis RJ; Sharma SK; Tolner B; Springer CJ; Martin J; Boxer GM; Bell J; Green AJ; Hartley JA; Cruickshank C; Wren J; Chester KA; Begent RH
    Clin Cancer Res; 2006 Nov; 12(21):6509-16. PubMed ID: 17085666
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Secretory production of single-chain antibody (scFv) in Brevibacillus choshinensis using novel fusion partner.
    Tokunaga M; Mizukami M; Yamasaki K; Tokunaga H; Onishi H; Hanagata H; Ishibashi M; Miyauchi A; Tsumoto K; Arakawa T
    Appl Microbiol Biotechnol; 2013 Oct; 97(19):8569-80. PubMed ID: 23334514
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts.
    Pavlinkova G; Beresford GW; Booth BJ; Batra SK; Colcher D
    J Nucl Med; 1999 Sep; 40(9):1536-46. PubMed ID: 10492377
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and biological evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine prodrugs for use in antibody-directed enzyme prodrug therapy.
    Masterson LA; Spanswick VJ; Hartley JA; Begent RH; Howard PW; Thurston DE
    Bioorg Med Chem Lett; 2006 Jan; 16(2):252-6. PubMed ID: 16290933
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins.
    Slavin-Chiorini DC; Kashmiri SV; Schlom J; Calvo B; Shu LM; Schott ME; Milenic DE; Snoy P; Carrasquillo J; Anderson K
    Cancer Res; 1995 Dec; 55(23 Suppl):5957s-5967s. PubMed ID: 7493377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
    Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
    Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Albumin-binding prodrugs of camptothecin and doxorubicin with an Ala-Leu-Ala-Leu-linker that are cleaved by cathepsin B: synthesis and antitumor efficacy.
    Schmid B; Chung DE; Warnecke A; Fichtner I; Kratz F
    Bioconjug Chem; 2007; 18(3):702-16. PubMed ID: 17378599
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Biological comparison of 149Pm-, 166Ho-, and 177Lu-DOTA-biotin pretargeted by CC49 scFv-streptavidin fusion protein in xenograft-bearing nude mice.
    Lewis MR; Zhang J; Jia F; Owen NK; Cutler CS; Embree MF; Schultz J; Theodore LJ; Ketring AR; Jurisson SS; Axworthy DB
    Nucl Med Biol; 2004 Feb; 31(2):213-23. PubMed ID: 15013487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
    Lu JY; Lowe DA; Kennedy MD; Low PS
    J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prodrugs of anthracyclines for use in antibody-directed enzyme prodrug therapy.
    Florent JC; Dong X; Gaudel G; Mitaku S; Monneret C; Gesson JP; Jacquesy JC; Mondon M; Renoux B; Andrianomenjanahary S; Michel S; Koch M; Tillequin F; Gerken M; Czech J; Straub R; Bosslet K
    J Med Chem; 1998 Sep; 41(19):3572-81. PubMed ID: 9733483
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.